Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.33 |
| ▸ | S100A10 | P60903 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461731 | 0.86 | KDM4E (0.39) | KDM4EMAPTAKR1B1ADORA2ATRPA1 | |
| SCHEMBL34461761 | 0.84 | TRPA1 (0.41) | TGM2KDM4EMAPTBTKAKR1B1 | |
| SCHEMBL34461736 | 0.83 | MEN1 (0.40) | KDM4EMAPTAKR1B1ADORA2ATRPA1 | |
| SCHEMBL34461721 | 0.75 | TRPA1 (0.40) | TGM2KDM4EMAPTAKR1B1TRPA1 | |
| SCHEMBL34461737 | 0.74 | TRPA1 (0.41) | TGM2KDM4EMAPTAKR1B1TRPA1 | |
| SCHEMBL31653782 | 0.74 | MAPT (0.42) | TGM2KDM4EMAPTAKR1B1RORC | |
| SCHEMBL34461717 | 0.73 | TRPA1 (0.42) | TGM2KDM4EMAPTBTKAKR1B1 | |
| SCHEMBL31677868 | 0.72 | RORC (0.40) | TGM2KDM4EMAPTAKR1B1RORC | |
| SCHEMBL31678840 | 0.72 | RORC (0.39) | TGM2KDM4EMAPTAKR1B1RORC | |
| SCHEMBL31678761 | 0.72 | MAPT (0.40) | TGM2KDM4EMAPTBTKAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | claimed |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | TGM2 4757/4885KDM4E 4779/4885MAPT 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.